The University of Rochester Wilmot Cancer Institute will receive $3.4 million over five years from the National Cancer Institute.
This grant will fund cancer treatment research, making NCI-supported clinical trials more accessible to patients.
“I’m so pleased that the University of Rochester has received this significant grant, which will help support their innovative and groundbreaking medical research,” said U.S. Rep. Joe Morelle, D-25th District. “I know all too well the devastating impact cancer can have on a family. Investments like this are essential to advancing research and education that will finally lead to a cure for this awful disease.”
The Wilmot Cancer Institute is one of 30 centers nationally to receive a Lead Academic Participating Site Grant. This funding supports research and infrastructure for clinical trials, and will allow the university to play a leadership role in setting national priorities for cancer-related clinical research.
“Clinical trials are a vital step in bringing new cancer treatments to patients,” said Paul Barr, who leads Wilmot’s Clinical Trials Office and is the principal investigator on this grant. “This funding will help us expand access to important national clinical trials in our region and ultimately shape cancer care nationwide.”